Market Overview:
The global acute coronary syndrome (ACS) market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of ACS, rising geriatric population, and technological advancements in the field of cardiology. Based on type, the global ACS market is segmented into monotherapy and combination therapy. The monotherapy segment is further sub-segmented into percutaneous coronary intervention (PCI), thrombolysis, and other therapies. The combination therapy segment is further sub-segmented into medical management and revascularization therapies. In terms of application, the global ACS market is divided into hospitals, ambulatory surgical center (ASC), and diagnostic centers. Geographically, the global ACS market is analyzed across North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . Some of the key players operating in this market are Boston Scientific Corporation (U.S.), Medtronic plc.(Ireland), Abbott Laboratories Inc.(U.S.), Stryker Corporation(U.S.), Becton Dickinson& Company(U.S.), Terumo Corporation(Japan), Edwards Lifesciences Corporation(U. S.
 Industry Outlook.svg)
Product Definition:
Acute coronary syndrome (ACS) is a group of conditions that describe a sudden and severe reduction in blood flow to the heart. This can be due to blockages in the coronary arteries (coronary artery disease) or rupture of a plaque in one of these arteries. The most common symptoms are chest pain (angina pectoris), shortness of breath, and sweating. ACS may lead to heart attack, unstable angina, or death.
Monotherapy:
Monotherapy is the treatment of choice for patients suffering from ACS. It's a single drug therapy and has fewer side effects as compared to Dual Therapy (MT) or even triple therapy (TT). The chances of getting side effects are less in monotherapy, hence it's more preferred by doctors and patients.
The growth factor responsible for the growth of this market is its preference by doctors over other therapies available in the market.
Combination Therapy:
According to the National Center for Biotechnology Information (NCBI), combination therapy is a technique wherein more than one drug or medication is used together to treat a particular disease. The most common example of such treatment includes the use of antibiotics and analgesics (painkillers) against toothache. According to NCBI, around 10% of patients suffering from chronic diseases experience adverse effects due to single-therapy and hence, it’s important that they are treated with combination therapies.
Application Insights:
Based on application, the global acute coronary syndrome (ACS) market is segmented into hospitals, ambulatory surgical centers, and diagnostic centers. The hospitals segment dominated the market in 2017 owing to increasing prevalence of chronic diseases such as heart attack and stroke. According to a study published by NCBI in 2018, around 5% of U.S. population aged 35 years or above suffered from some form of cardiovascular disease (CVD) during 2015-2017 period which was followed by about 3% during 1995-1999 period and 1% during 1985-1995 period respectively. Thus rising incidences of CVDs are expected to fuel demand for effective treatment methods such as ACS therapy drugs in the forthcoming years which will further boost growth over forecast period.
The ambulatory surgical center segment is anticipated to witness lucrative growth over forecast period due to growing awareness among patients regarding timely treatment after suffering from an acute coronary syndrome (ACS).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to favorable reimbursement policies, high healthcare expenditure, and increasing awareness about early diagnosis of acute coronary syndrome (ACS). In addition, presence of key players such as Johnson & Johnson; Merck & Co., Inc.; and Pfizer Inc. is expected to drive the growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to improving healthcare infrastructure coupled with rising disposable income in emerging countries such as China and India. Moreover, growing medical tourism industry will also boost demand for diagnostic procedures associated with acute coronary syndrome thus driving revenue generation in this region over the next eight years.
Growth Factors:
- Increasing incidence of ACS: The incidence of ACS is increasing globally due to the changing lifestyle and dietary habits. This is propelling the growth of the ACS market.
- Growing awareness about ACS: There is a growing awareness about ACS among people due to increasing incidences of heart attacks and strokes. This is fuelling demand for diagnosis and treatment services for ACS, thereby driving the growth of the market.
- Rising prevalence of risk factors for developing ACs: The prevalence of risk factors such as obesity, hypertension, smoking, and diabetes is rising globally which is leading to an increase in cases of ACs. This is boosting demand for diagnosis and treatment services for ACs, thereby driving market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Coronary Syndrome (ACS) Market Research Report
By Type
Monotherapy, Combination Therapy
By Application
Hospitals, Ambulatory Surgical Center, Diagnostic Centers
By Companies
Dexa Medica, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Serum Institute of India, Biogen, Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Acute Coronary Syndrome (ACS) Market Report Segments:
The global Acute Coronary Syndrome (ACS) market is segmented on the basis of:
Types
Monotherapy, Combination Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Center, Diagnostic Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dexa Medica
- GlaxoSmithKline
- Novartis
- Pfizer
- Sanofi
- Serum Institute of India
- Biogen
- Eli Lilly and Company
 Market Overview.svg)
Highlights of The Acute Coronary Syndrome (ACS) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monotherapy
- Combination Therapy
- By Application:
- Hospitals
- Ambulatory Surgical Center
- Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Coronary Syndrome (ACS) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute Coronary Syndrome (ACS) is a serious medical condition that can cause chest pain, shortness of breath, and heart attack. ACS is most commonly caused by a blockage in one or more coronary arteries.
Some of the key players operating in the acute coronary syndrome (acs) market are Dexa Medica, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Serum Institute of India, Biogen, Eli Lilly and Company.
The acute coronary syndrome (acs) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Coronary Syndrome (ACS) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Coronary Syndrome (ACS) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Coronary Syndrome (ACS) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Coronary Syndrome (ACS) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Coronary Syndrome (ACS) Market Size & Forecast, 2020-2028
4.5.1 Acute Coronary Syndrome (ACS) Market Size and Y-o-Y Growth
4.5.2 Acute Coronary Syndrome (ACS) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monotherapy
5.2.2 Combination Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Center
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Coronary Syndrome (ACS) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Coronary Syndrome (ACS) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monotherapy
9.6.2 Combination Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Center
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monotherapy
10.6.2 Combination Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Center
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monotherapy
11.6.2 Combination Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Center
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monotherapy
12.6.2 Combination Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Center
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monotherapy
13.6.2 Combination Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Center
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Coronary Syndrome (ACS) Market: Competitive Dashboard
14.2 Global Acute Coronary Syndrome (ACS) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dexa Medica
14.3.2 GlaxoSmithKline
14.3.3 Novartis
14.3.4 Pfizer
14.3.5 Sanofi
14.3.6 Serum Institute of India
14.3.7 Biogen
14.3.8 Eli Lilly and Company
